Smart Ring vs CGM (2026): What Each Actually Measures

Modern consumer smart rings (Oura Ring 4, Ultrahuman Ring Air, RingConn Gen 2, Samsung Galaxy Ring) share a near-identical sensor stack:

• Photoplethysmography (PPG) sensors - green, red, and infrared LEDs pulsing against the finger to detect blood volume changes. PPG produces heart rate, heart rate variability (HRV), blood oxygen (SpO2), and respiratory rate.
• Skin temperature sensors - thermistors against the palmar finger surface measuring skin temperature with ~0.1 degree resolution. Used to detect circadian rhythm shifts and (in some models) menstrual cycle phase.
• 3-axis accelerometer - movement and step count, and during sleep, posture detection.

That sensor stack is mature enough to produce reliable measurements of physiological signals in the cardiovascular, respiratory, and circadian domains. The output metrics depend on signal processing software rather than additional sensors - Oura's readiness score, Ultrahuman's metabolic score, and similar aggregate metrics are all derived from this same raw sensor input.

What the sensor stack cannot do: measure anything that requires direct contact with interstitial fluid, blood, or tissue beneath the skin. Glucose, electrolytes, hormones, lactate, ketones, and any chemical analyte are out of reach for current consumer PPG-based devices.

A continuous glucose monitor measures glucose concentration in the interstitial fluid between cells, not in the bloodstream directly. A small sensor filament (typically 5-6mm long) is inserted just under the skin via a single-use applicator and sits in the subcutaneous tissue for 7-14 days. The sensor uses glucose-oxidase enzymatic detection to convert glucose into an electrical signal proportional to its concentration.

Interstitial-fluid glucose lags blood glucose by approximately 5-15 minutes depending on whether glucose is rising or falling. Modern CGMs report glucose readings every 1-5 minutes, which is sufficient to track meal responses, exercise responses, and overnight stability.

The two consumer-relevant CGM platforms in 2026 are:

• Abbott FreeStyle Libre 3 - 14-day sensor wear, no fingerprick calibration required, smartphone reader, available on NHS prescription for Type 1 diabetes and selected Type 2 cases.
• Dexcom G7 - 10-day sensor wear, smartphone integration including Apple Watch and Android Wear, FDA-cleared for over-the-counter use as of 2024 (UK availability via private prescription).

Newer entrants like Levels Health and ZOE bundle FreeStyle Libre or Dexcom sensors with their own app + nutrition coaching, but the underlying hardware is the same. In 2026 there is no UK or US consumer CGM that measures glucose non-invasively.

The short answer: the physics doesn't work yet. Glucose is a small, electrically neutral molecule whose optical signature is buried in a much louder background of water absorption and lipid absorption. Non-invasive optical detection of blood glucose requires distinguishing a glucose-specific signal at concentrations around 5 mmol/L from interference signals that are 100-1000x stronger.

Research into non-invasive optical glucose monitoring has been ongoing since the 1990s. Most candidate technologies (near-infrared spectroscopy, Raman spectroscopy, mid-infrared, photoacoustic, dielectric) can produce a glucose-correlated signal under laboratory conditions but fail to maintain calibration under real-world conditions - skin temperature changes, hydration changes, individual skin pigmentation, and pressure variation all degrade the signal-to-noise ratio enough to make standalone consumer products unreliable.

The FDA's February 2024 safety communication explicitly listed smart rings and smartwatches as devices that should not be used to measure blood glucose levels. The communication was a response to a wave of unbranded products marketed via social media as 'non-invasive glucose monitors' - typically pulse-oximetry rings rebadged with glucose-tracking software that produces fictitious readings unrelated to actual blood glucose.

Reliable, validated non-invasive glucose monitoring may eventually arrive (research from companies like Nemaura Medical's sugarBEAT and Movano Health is ongoing) but as of 2026 nothing on the consumer market measures actual blood glucose through a smart ring or smartwatch form factor.